H19 and breast carcinoma: H19 is also delivered by exosomes to promote gefitinib resistance in NSCLC cells.[131] Pan and Zhou further suggest the role of exosomal H19 in erlotinib resistance in NSCLC, in which H19 promotes resistance via targeting miR‐615‐3p to upregulate ATG7 expression.[132] Wang et al. show that exosome‐mediated transfer of H19 to sensitive cells leads to disseminate DOX resistance in breast cancer.[133]